Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Modulation of oxidative stress as an anticancer strategy

Modulation of oxidative stress as an anticancer strategy The role of reactive oxygen species (ROS) in tumorigenesis is controversial, as they have been shown to have both tumour-promoting and tumour-inhibiting properties. Although low to moderate ROS levels can be beneficial to cells by promoting proliferation pathways and DNA mutagenesis, high ROS levels can instead become detrimental and induce cell death. Recent work has shown that multiple antioxidant pathways that inhibit ROS are upregulated during tumour initiation and progression. These antioxidant pathways are composed of a multitude of both metabolic and non-metabolic enzymes, many of which can be targeted for inhibition. Numerous standard chemotherapies are cytotoxic towards cancer cells owing to their ability to induce drastic increases in ROS levels. The development of novel targeted therapies against antioxidant pathways may yield considerable benefits to the field of cancer treatment. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Nature Reviews Drug Discovery Springer Journals

Modulation of oxidative stress as an anticancer strategy

Download PDF
17 pages

Loading next page...
 
/lp/springer-journals/modulation-of-oxidative-stress-as-an-anticancer-strategy-6EZR12lkPe

References (244)

Publisher
Springer Journals
Copyright
Copyright © 2013 by Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.
Subject
Biomedicine; Biomedicine, general; Pharmacology/Toxicology; Biotechnology; Medicinal Chemistry; Molecular Medicine; Cancer Research
ISSN
1474-1776
eISSN
1474-1784
DOI
10.1038/nrd4002
Publisher site
See Article on Publisher Site

Abstract

The role of reactive oxygen species (ROS) in tumorigenesis is controversial, as they have been shown to have both tumour-promoting and tumour-inhibiting properties. Although low to moderate ROS levels can be beneficial to cells by promoting proliferation pathways and DNA mutagenesis, high ROS levels can instead become detrimental and induce cell death. Recent work has shown that multiple antioxidant pathways that inhibit ROS are upregulated during tumour initiation and progression. These antioxidant pathways are composed of a multitude of both metabolic and non-metabolic enzymes, many of which can be targeted for inhibition. Numerous standard chemotherapies are cytotoxic towards cancer cells owing to their ability to induce drastic increases in ROS levels. The development of novel targeted therapies against antioxidant pathways may yield considerable benefits to the field of cancer treatment.

Journal

Nature Reviews Drug Discovery – Springer Journals

Published: Nov 29, 2013

There are no references for this article.